Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Cognition Therapeutics (NASDAQ:CGTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold [Seeking Alpha]